Structured fixed-bed bioreactors offer vaccine manufacturers a scalable, lower-cost alternative to roller bottles and microcarrier systems.
Thomas Robert
Advertisement
Thomas Robert, PhD, is senior innovation and scientific affairs lead at Univercells Technologies.
Articles by Thomas Robert
Advertisement
Latest Updated Articles
Rethinking the Cell Culture Platform Behind Vaccine ManufacturingSeptember 25th 2026
Advertisement
Advertisement
Trending on BioPharm International
1
Shilpa CDMO Commits $50 Million to Scale Peptide Capacity in India
2
Policy Leaders Urge Treasury to Narrow Biotech Outbound Investment Rule
3
Lonza to Acquire Merck KGaA’s US CDMO Business, Adding ADC, Viral Vector, and LNP Capacity
4
Spyre’s Anti-TL1A Antibody SPY072 Misses in Psoriatic Arthritis and Axial Spondyloarthritis, Shifts Focus to Hidradenitis Suppurativa
5